Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides

Abstract

The invention relates to the compositions of synthetic oligo-γ-(1→6)-2-amino-2-deoxy-D-glu-copyranosides conjugated to carriers, and methods for making and use same.

What is claimed is: 
     
         1 - 59 . (canceled) 
     
     
         60 . A method for stimulating an immune response in a subject comprising
 administering to a subject in need thereof the oligosaccharide-carrier conjugate in an amount effective to stimulate an immune response in the subject,   wherein the oligosaccharide-carrier conjugated comprises an oligosaccharide conjugated to a protein or peptide carrier, through a linker, wherein the oligosaccharide is a β-1,6-linked glucosamine that is 0-40% acetylated and 4-20 monomers in length.   
     
     
         61 . The method of  claim 60 , wherein the oligosaccharide is 5-11 monomers in length. 
     
     
         62 . The method of  claim 60 , wherein the oligosaccharide is 5 monomers in length. 
     
     
         63 . The method of  claim 60 , wherein the oligosaccharide is 0% acetylated. 
     
     
         64 . The method of  claim 60 , wherein the protein or peptide carrier is tetanus toxoid. 
     
     
         65 . The method of  claim 60 , wherein the oligosaccharide-carrier conjugate has an oligosaccharide to carrier ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1. 
     
     
         66 . The method of  claim 60 , wherein the oligosaccharide-carrier conjugate has an oligosaccharide to carrier ratio in the range of 10:1 to 50:1. 
     
     
         67 . The method of  claim 60 , wherein the oligosaccharide-carrier conjugate has an oligosaccharide to carrier ratio in the range of 40:1. 
     
     
         68 . The method of  claim 60 , free of microbial contaminants other than tetanus toxoid or components thereof. 
     
     
         69 . The method of  claim 60 , wherein the subject is human. 
     
     
         70 . The method of  claim 60 , wherein the subject is non-human. 
     
     
         71 . The method of  claim 60 , wherein the oligosaccharide-carrier conjugate is administered to the subject prior to surgery. 
     
     
         72 . The method of  claim 71 , wherein the surgery is implant surgery. 
     
     
         73 . The method of  claim 71 , wherein the oligosaccharide-carrier conjugate is administered with an adjuvant. 
     
     
         74 . The method of  claim 72 , wherein the oligosaccharide is 0% acetylated and the carrier is tetanus toxoid.